Psychedelics Become the Winter Wellness Trend

Psychedelics have been creeping their way into the wellness industry since 2018, but they are taking on a new meaning with research showing their benefits for mental illness.

Psychedelic Mushroom

Researchers continue to look into the wellness benefits of psychedelic drugs like psilocybin as it remains a frontrunner in wellness trends. More specifically, these drugs are being analyzed for their potential mental health benefits, like relieving anxiety, depression and panic disorders. 

Over the past decade, research published by John Hopkins University, Imperial College of London and Yale University has shown how psychedelic medicines like MDMA, psilocybin and ketamine can be used in a safe and effective manner as a treatment to a variety of mental health conditions. 

Related: Magic Mushrooms Take Wellness Tourism on a Trip

With mental illness rising around the world due to the Covid-19 pandemic, and current mental illness medication having numerous side effects, many people are trying to find a more natural route to treat their mental health concerns. Mydecine Innovations Group, a life sciences parent company, is focused on developing and producing psychedelic medicine naturally derived from fungi, therapeutic solutions and functional natural health benefits. 

In September 2020, Mydecine Innovations completed the acquisition of NeuroPharm, a developer of natural health, psychedelic-based treatments for mental disorders. Currently, NeuroPharm is conducting clinical trials to study psychedelics for the treatment of post-traumatic stress disorder (PTSD). 

Mydecine Innovations also launched Mindleap, a psychedelics-focused digital telehealth platform. This health app is designed to provide an additional step in fighting against mental illness, and it helps consumers track their mental health and connect with trained mental health specialists for aftercare. 

Compass Pathways is another company looking toward the use of psychedelics in treatment mental illness. Its proprietary formulation of synthetic psilocybin is undergoing a Phase 2B clinical trial in 216 patients with TRD in 20 sites across Europe and North America. 

Related: Mushroom Magic Making Its Way Into the Spa

More in Therapies